-
1 week ago | 
pf-media.co.uk | Emma Cooper
Lemer Pax, a worldwide leader in innovative radiation protection solutions, and Synapse Medical, the Diagnostic Imaging division of Uniphar Medtech, are proud to announce a strategic partnership that will expand the distribution of Lemer Pax’s comprehensive portfolio of medical radiation protection products across the UK, effective from 1st April 2025.
-
1 week ago | 
pf-media.co.uk | Emma Cooper
The National Institute for Health and Care Excellence (NICE) has recommended AstraZeneca’s capivasertib (also called Truqap) with fulvestrant as an option for around 1,100 adults with hormone receptor (HR)-positive HER2-negative breast cancer that has certain genetic mutations and has spread.
-
2 weeks ago | 
pf-media.co.uk | Emma Cooper
Maxwellia, the consumer healthcare company dedicated to widening access to medicines, is pleased to announce the appointment of Alexandra Trehane as Chief Operating Officer (COO). Alexandra brings extensive experience in operations, strategy, and commercial execution. In her new role, she will oversee the company’s day-to-day processes, ensuring continued efficiency and innovation as Maxwellia scales to meet increasing demand for its game-changing over the counter (OTC) medicines.
-
3 weeks ago | 
pf-media.co.uk | Emma Cooper
The National Institute for Health and Care Excellence (NICE) has recommended brentuximab vedotin in combination with doxorubicin, vinblastine and dacarbazine (AVD) to treat adult patients with untreated stage 3 or 4 CD30+ Hodgkin lymphoma (HL), within final draft guidance (FDG)1.
-
3 weeks ago | 
pf-media.co.uk | Emma Cooper
Full-service Cell and Gene Therapy (CGT) CDMO eXmoor Pharma has appointed Dr James Miskin as Non-Executive Director following his 23-year tenure at Oxford Biomedica. There, James oversaw delivery of the first-ever commercial batches of lentiviral vectors to manufacture the first FDA-approved CAR-T therapy, which has now been dosed in over 8,000 patients globally.
-
1 month ago | 
pf-media.co.uk | Emma Cooper
Allegro NV, a biomedical company developing transformative nanotechnology-based treatments for degenerative joint disease, has found that hydrocelin (ALG-001), its injectable microparticle hydrogel, showed no signs of toxicity in two preclinical studies conducted for periods of 4 and 13 weeks respectively. The positive results build on hydrocelin’s clean safety profile immediately following treatment, established in previously published preclinical studies.
-
1 month ago | 
pf-media.co.uk | Emma Cooper
Around 1,000 women per year with endometriosis could benefit from a new treatment that starts working more quickly than injectable alternatives, can be taken at home rather than at clinics, combines all needed hormones in one pill and returns hormone levels to normal faster when stopped.
-
1 month ago | 
pf-media.co.uk | Emma Cooper
Reforms to reduce bureaucracy, make savings and empower NHS staff to deliver better care for patients have been set out by the Prime Minister, Keir Starmer. NHS England will be brought back into the Department of Health and Social Care (DHSC) to put an end to the duplication resulting from two organisations doing the same job in a system currently holding staff back from delivering for patients.
-
1 month ago | 
pf-media.co.uk | Emma Cooper
England is the first country in Europe to provide access to MAVENCLAD® (cladribine tablets) for adults with active relapsing‐remitting multiple sclerosis (RRMS). The National Institute for Health and Care Excellence (NICE) published its Final Draft Guidance (FDG) recommending cladribine tablets as a first-line option for treating RRMS in adults with active disease* when high-efficacy disease-modifying therapies (DMTs) would be considered1.
-
1 month ago | 
pf-media.co.uk | Emma Cooper
CordenPharma, a Contract Development & Manufacturing Organization (CDMO) specialising in the supply of peptide APIs and peptide-based therapeutic finished dosage drug products, has announced the signing of a strategic partnership with Viking Therapeutics, a clinical stage company focused on developing novel therapies for metabolic and endocrine disorders.
